Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02557862 1997-03-28
PROCESS TO PREPARE 5-AMINOMETHYL SUBSTITUTED OXAZOLIDINONES
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a process for transformation of the 5-
hydroxymethyl substituted oxazolidinone alcohols (III) to the corresponding S-
aminomethyl substituted oxazolidinone amines (VII) which are useful in the
production
of oxazolidinone antibacterial pharmaceuticals (VIII).
2. Description of the Related Art
US Patents 5,164,510, 5,182,403 and 5,225,565 disclose 5'-
indolinyloxazolidinones, 3-(5'-indazolyl)oxazolidinones, 3-(fused-ring
substituted)phenyloxazolidinones respectively useful as antibacterial agents.
US Patents 5,231,188 and 5,247,090 disclose various tricyclic [6.5.5] and
[6.6.5]-fused ring oxazolidinones useful as antibacterial agents.
International Publication W093/09103 discloses mono- and di-halo phenyl
oxazolidinone anti-bacterials which are useful as pharmaceutical agents for
their
anti-bacterial action.
US 4,150,029, 4,250,318, 4,476,136, 4,340,606 and 4,461,773 disclose the
synthesis of 5-hydroxymethyloxazolidinones from amines (R-NHX1, where X1 is -H
or p-toluenesulfonyl) and R,S-glycidol (C*H2-O-C*H-CH2-OH where the carbon
atoms marked* are bonded together, cyclized to form an epoxide). The mixture
of
enantiomers produced by this process (represented by the formula R-NH-CH2-
CHOH-CH2-OH) are separated by fractional crystallization of the mandelic acid
salts. The enantiomerically pure R-diol is then converted into the
corresponding 5R-
hydroxymethyl substituted oxazolidinones (III) by condensation with
diethylcarbonate in the presence of sodium methoxide. These 5R-hydroxymethyl
substituted oxazolidinones are useful as synthetic precursors of
pharmaceutically
useful oxazolidinones. The large number of steps renders this process
unattractive.
J. Med. Chem., 32, 1673 (1989), Tetrahedron 45, 1323 (1989) and US Patent
4,948,801 disclose a method of producing oxazolidinones which comprises
reacting an
isocyanate (R-N=C=O) with (R)-glycidyl butyrate in the presence of a catalytic
amount of lithium bromide - tributylphosphine oxide complex to produce the
corresponding 5R-butyryloxymethyl substituted oxazolidinone. The process is
1
CA 02557862 1997-03-28
performed at 135-145°. The butyrate ester is then hydrolyzed in a
subsequent step
to give the corresponding 5-hydroxymethyl substituted oxazolidinone. The
relative
high cost and/or availability of the isocyanate starting material and
requirement of
high temperature detract significantly from the attractiveness of this method.
Abstracts of Papers, 206th National Meeting of the American Chemical
Society, Chicago, IL, August, 1993; American Chemical Society: Washington, DC,
1993; ORGN 089; J. Med. Chem. 39, 673 (1996); J. Med. Chem. 39, 680 (1996);
Intzrnational Publications W093l09103, W093/09103, W095/07271 and
W093/23384; Canadian Patent Applications No. 2,201,736 and 2,200,433;
Abstracts of
Papers, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy,
San Francisco, CA, September, 1995; American Society for Microbiology:
Washington, DC, 1995; Abstract No. F208; Abstracts of Papers, 35th
Interscience
Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA,
September, 1995; American Society for Microbiology: Washington, DC, 1995;
Abstract No. F207; Abstracts of Papers, 35th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1995;
American Society for Microbiology: Washington, DC, 1995; Abstract No. F206;
Abstracts of Papers, 35th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, September, 1995; American Society for
Microbiology: Washington, DC, 1995; Abstract No. F227;
disclose the reaction of a carbamate with n-butyllithium, lithium
diisopropylamide
or lithium hexamethyldisilazide at -78° to -40° followed by
glycidyl butyrate at -78°
followed by warming to 20-25° to produce 5-hydroxymethyl substituted
oxazolidinones (III) where the ester is cleaved during the reaction.
US Patents 4,062,862 and 4,236,012 disclose a process to prepare
oxazolidinones which comprises reacting an epoxide with a primary (lacking any
substituent on the nitrogen atom) carbamate in the presence of a catalyst. The
process "is preferably conducted at a temperature of from 100° to
150° for several
hours."
Canadian Patent 681,830 discloses a process to prepare oxazolidinones which
comprises reacting an aryl ether of glycidol with a primary carbamate in the
presence of an alkaline catalyst (preferably lithium amide or lithium
hydroxide).
The process was performed in the "preferred temperature range of 150°
to 165°".
The products are aryl ethers of 5-hydroxymethyl substituted oxazolidinones and
the
yields are poor (40-78%).
2
CA 02557862 1997-03-28
J. Am Chem. Soc., 64, 1291 (1942) and US Patent 3,547,951 disclose a
method for converting primary alcohols to amines that involves treatment with
methane sulfonyl chloride to produce the mesylate followed by contacting the
mesylate with anhydrous ammonia at ambient temperature in a sealed reaction
vessel under high pressure.
It is also known that the mesylates of primary alcohols react with aqueous
ammonia to give the corresponding primary amines, but high temperature and
high
pressure (85 psig) are required. Normally this process cannot be used in
ordinary
general purpose reactors and must be run in special reactors rated for high
pressure.
International Publication W095/07271 discloses the ammonolysis of
oxazolidinone mesylates.
US Patent 4,476,136 discloses a method of transforming 5-hydroxymethyl
substituted oxazolidinones (III) to the corresponding 5(S)-aminomethyl
substituted
oxazolidinones (VII) that involves treatment with methane sulfonyl chloride
followed
by potassium phthalimide followed by hydrazine. This reaction sequence
produces
by-products which are difficult to separate from the desired product.
J. Med. Chem., 32, 1673 (1989) and Tetrahedron 45, 1323 (1989) disclose a
method for transforming 5-hydroxymethylsubstituted oxazolidinones into the
corresponding 5S-acetamidomethyl substituted oxazolidinones that involves
treatment with methanesulfonyl chloride or tosyl chloride, followed by sodium
azide,
followed by trimethylphosphite or platinum dioxidelhydrogen, followed by
acetic
anhydride or acetyl chloride to give the desired 5(S)-acetamidomethyl
substituted
oxazolidinone. It is known that sodium azide is an explosion hazard.
US Patent 5,210,303 discloses the conversion of various substituted benzyl
chlorides into the corresponding benzylamines by heating with aqueous ammonia
in
the presence of aromatic aldehydes to suppress dialkylation. The dialkylated
impurity is generally difficult to remove; see Chem. Lett., 1057 (1978).
SITMMARY OF INVENTION
Disclosed is a process to prepare 5-aminomethyl substituted oxazolidinones of
formula (VII)
O
(VII)
i
~N O
~-H
CH2 NH2
3
CA 02557862 1997-03-28
where R1 is
X~
Q~ / \
X2
where X1 is -H or -F;
where X2 is -H or -F;
where Q1 is:
A2
A~ CH2)~
a)
Z' - N
Z2
b)
N
(CH2)m
Z3i
C)
N
R~
d) ~N
N
4
CA 02557862 1997-03-28
N-
N
g> N -
NON/
h)
N
~N
N
/~ N
N~N\
N
k) N -
N
m
R7 - N~
5
CA 02557862 1997-03-28
Q 1 and X2 taken together are:
Rs
\ N
~5
where Z1
is:
a) -CH2-,
b) -CH(R4)-CH2-,
c) -C(O)-, or
d) -CH2CH2CH2-;
where Z2
is:
a) -OZS-,
b) -O-,
c) -N(R7)-,
d) -OS-, or
e) -S-;
where Z3
is:
a) -02S-,
b) -0-,
c) -OS-, or
d) -S-;
where A1
is:
a) H- or
b) CH3;
where A2
is:
a) H-,
b) HO-,
c) CH3-,
d) CH30-,
e) R20-CH2-C(O)-NH-
R30-C(O)-NH-,
g) (Cl-C2)alkyl-O-C(O)-,
h) HO-CH2-,
i) CH30-NH-,
j) (C1-C3)alkyl-02C-
6
CA 02557862 1997-03-28
k) CH3-C(O)-,
1) CH3-C(O)-CH2-,
m) \~>~~
O O
n)
A1 and A2 taken together are:
R~2
o-~- ,~,~"'
a)
b) o=
Rya
c) N=
where R1 is:
a) -CHO,
b) -COCH3,
c) -COCHCl2,
d) -COCHF2,
e) -C02CH3,
f7 -S02CH3, or
g) -COCH20H;
where R2 is:
a) H-,
b) CH3-,
c) phenyl-CH2-,
or
d) CH3C(O)-;
where R3 is:
a) (C1-C3)alkyl-,
or
7
CA 02557862 1997-03-28
b) phenyl-;
where R4
is:
a) H-, or
b) HO-;
where R5
is:
a) H-,
b) (C1-Cg)all~yl-,
c) CH2 = CH-CH2-
or
d) CH3-O-(CH2)2';
where
R6 is:
a) CH3-C(0)-,
b) H-C(O)-,
c) C12CH-C(O)-,
d) HOCH2-C(O)-,
e) CH3S02-,
R S C(O)
15
g) F2CHC(O)-,
N /~ N ~ C (O)
h)
i) H3C-C(0)-0-CH2-C(O)-,
j) H-C(O)-0-CH2-C(0)-,
C(
1) HC--__ CH-CH20-CH2-C(O)- or
m) phenyl-CH2-O-CH2-C(O)-;
where R7 is:
a) R20-C(R10)(Rll)-C(0)_~
b) R30-C(O)-,
c) R8-C(O)-,
8
CA 02557862 1997-03-28
O
d) ,
O
H
O
e) , ,
O O
H
HgC-C(O)-(CH2)2-C(O)-
g) R9_S02_~
h) O
O
r~
O
i) HO-CH2-C(O)-,
j) R16-(CH2)2-,
k) R13-C(O)-O-CH2-C(O)-,
1) (CH3)2N-CH2-C(O)-NH-,
m) NC-CH2- or
n) F2-CH-CHZ-;
where Ra is:
a) H-,
b) (C1-C4)alkyl,
c) aryl -(CHZ)p,
d) CIHzC-,
e) C12HC-,
f7 FH2C-,
g) F2HC- or
h) (C3-Cs)cycloalkyl;
where R9 is:
9
CA 02557862 1997-03-28
a) -CH3,
b) -CH2C1,
c) -CH2CH=CH2,
d) aryl or
e) -CH2CN;
where Rl~ H- or CH3-;
is
where Rll H- or CH3-;
is
where R12
is:
a) H-,
b) CH30-CH20-CH2- or
c) HOCHZ-;
where R13
is:
a) CH3-,
b) HOCH2-,
c) (CH3)21V-phenyl, or
d) (CH3)2N-CH2_;
where R14 :
is
a) HO-,
b) CH30-,
c) H~-,
d) CH30-C(O)-0-,
e) CH3-C(O)-O-CH2-C(O)-O-,
phenyl-CH2-O-CH2-C(0)-O-,
g) HO-(CH2)2-0-,
h) CH30-CH2-0-(CH2)2-O-,
or
i) CH30-CH2-O-;
where R15
is:
a) H- or
b) Cl-;
where Rls s:
i
a) HO-
b) CHgO-, or
c) F;
where m is 0 or 1;
where n is 1 thru 3;
CA 02557862 1997-03-28
where p is 0 or 1;
where aryl is phenyl substituted with zero (0) or one (1) of the following:
a) -F,
b) -Cl,
c) -OCH3,
d) -OH,
e) -NH2,
fl -(C1-C4)~Yl~
g) -O-C(O)-OCH3, or
h) -N02 and protected forms thereof,
which comprises:
(1) contacting 5-hydroxymethyl substituted oxazolidinone alcohols of formula
CA 02557862 1997-03-28
(III)
O
(III)
~N O
~_ H
CH2 OH
where Rl is as defined above with a sulfonylating agent selected from the
group
consisting of compounds of formula (Va Vd)
M3-S02-C6Hn3(N02)nlCln2 Via)
O~-S02-Cslia3(N02)nlCln2]2 (Vb)
O(S02-F)2 (Vc)
O(S02-CF3)2 ~d)
where n1 is 0, 1 or 2;
where n2 is 0 thru 4 with the provisos that:
if n1 is 0, n2 is 2, 3 or 4,
if n 1 is 1, n2 is 0 or 1,
ifnlis2,n2is0;
where n3 is 5 - (n1 + n2);
where M3 is Cl- or Br- to produce the corresponding oxazolidinone sulfonate
of formula (VIa VId)
0
R~ ~
~N~O
H (VIa or VIb)
CH2- O - S02- CsH~ (N02)~~ CI~
O
R, ~ (VIc)
~N O
~CH -O- SO - F
2 2
O
R~ ~
~N~O
(VId)
CH2- O - S02-CF3
12
CA 02557862 1997-03-28
and
(2) contacting the oxazolidinone sulfonate (VIa VId) with ammonia at a
pressure of less than about 30 psig.
DETAILED DESCRIPTION OF THE INVENTION
The process to produce the 5-hydroxymethyl substituted oxazolidinone
alcohols (III) can use either the non-cyclic (S)-, (R)- dihydroxy compounds of
formula
(I) or any mixture thereof or (S)-, (R)- glycidol (IV) or any mixture to
couple with the
carbamate (IIA) or a trifluoroacetamide of formula (IIB).
The 5-hydroxymethyl substituted oxazolidinone alcohols (III) are useful
intermediates to produce 5-aminomethyl substituted oxazolidinone amines (VII)
which can be acylated to prepare pharmaceutically useful 5-acylamidomethyl
substituted oxazolidinone (VIII) antibacterial agents. Because of an
enantiomeric
center, 5(R)-, 5(S)-acylamidomethyl substituted oxazolidinones (VIII) and
mixtures
thereof can be produced. The 5-acylamidomethyl substituted oxazolidinone
(VIII)
(S)-enantiomer has antibacterial activity, the (R)-enantiomer does not. The
5(S)-
aminomethyl substituted oxazolidinone amine (VII) enantiomer is produced from
the
5(R)-hydroxymethyl substituted oxazolidinone alcohol (III) enantiomer which is
produced from the (S)-dihydroxy compound (I) or (S)-glycidol (IV). Therefore,
the
desired and preferred enantiomeric sequence is to use enantiomerically pure
(S)-
dihydroxy compound (I) or (S)-glycidol (IV) to give (R)-5-hydroxymethyl
substituted
oxazolidinone alcohol (III) which is used to give enantiomerically pure (S)-5-
aminomethyl substituted oxazolidinone amine (VII) which is transformed to
enantiomerically pure (S)-5-acylamidomethyl substituted oxazolidinone (VIII).
However, it is readily apparent to one skilled in the art that one could
easily
perform the identical process steps with the opposite enantiomeric forms and
at any
point in the process invert an undesired enantiomeric configuration to the
desired
one. Therefore, using the chemistry of the claimed process with any of the
enantiomeric forms is considered equivalent to the claimed processes.
The dihydroxy compounds, Ml-CH2-CH(OH)-CHZ-OH, of formula (I) and
glycidol compounds, C*H2-C*H-CH2-OH, of formula (IV) where the carbon atoms
designated by an * are each bonded to the same oxygen atom (-O-) to form a
three
member ring, are known to those skilled in the art or can be readily prepared
from
known compounds by methods known to those skilled in the art. It is preferred
that
the hydroxy starting material be the dihydroxy compound (I). It is preferred
that
the dihydroxy compound (I) and the glycidol (IV) be the (S)-enantiomer. It is
13
CA 02557862 1997-03-28
preferred that Ml is Cl-; it is preferred that the dihydroxy compound (I) be
claim 5,
which can be purchased commercially.
The carbamates, R1-NH-CO-O-M2, of formula (IIA) and the
trifluoroacetamide, R1-NH-CO-CF3, of formula (IIB) are either known to those
skilled in the art or can readily be prepared from known compounds by methods
known to those skilled in the art. The nature of the leaving group M2 is not
important since it is lost during the course of the reaction as is known to
those
skilled in the art. Operable M2 (leaving groups) are those where -O-M2 is a
base
whose acid has a pka of between about 8 and about 24. Preferred M2 includes
C1-C20 alkyl,
C3-C7 cycloalkyl,
~- optionally substituted with one or two C1-C3 alkyl or F-, Cl-, Br-, I-,
CH2=CH-CH2-,
CH3-CH=CH-CH2-,
(CH3)2C=CH-CH2-,
CH2=CH-,
~-CH=CH-CH2-,
~-CH2- optionally substituted on ~- with one or two -Cl, C1-C4 alkyl, -N02,
-CN, -CF3,
9-fluorenylmethyl,
(Cl)3C-CH2-,
2-trimethylsilylethyl,
~-CH2-CH2-,
1-adamantyl,
(~)2CH-,
CH--_C-C(CH3)2-
2-furanylmethyl,
isobornyl, more preferred leaving groups are Cl-C4 alkyl or benzyl. Any
other leaving group which operates in a similar manner is considered
equivalent to
those identified above. The carbamate (IIA) and trifluoroacetamide (IIB) carry
the
aromatic,/heteroaromatic group (R1-) of the 5-hydroxymethyl substituted
oxazolidinone alcohol (III). It is preferred that R1 is phenyl substituted
with one -F
and one substituted amino group; it is more preferred that Rl is 3-fluoro-4-[4-
(benzyloxycarbonyl)-1-piperazinyl]phenyl or 3-fluoro-4-(4-morpholinyl)phenyl.
Depending on the particular substituents in R1, the groups may have to be
protected
14
CA 02557862 1997-03-28
as is known to those skilled in the art, by means known to those skilled in
the art to
prevent undesirable side reactions. For example, if the Rl substituent has a
free
primary or secondary hydroxy group, it is not necessary, but preferable to
protect it
with an alcohol protecting group in the formation of the 5-hydroxymethyl
substituted oxazolidinone alcohols (III). The unprotected alcohol will not in
general
interfere with the reaction of the dihydroxy compound (I) or glycidol (I~ with
the
carbamate (IIA) or trifluoroacetamide (IIB) to give the 5-hydroxymethyl
substituted
oxazolidinone alcohols (III). However, an unprotected alcohol will in general
interfer
with the conversion of the 5-hydroxymethyl substituted oxazolidinone alcohols
(III)
to the corresponding 5-aminomethyl substituted oxazolidinone amines (VII),
because
it is very difficult or impossible to selectively protect a primary or
secondary alcohol
on the R1 functionality in the presence of another primary or secondary
alcohol.
Suitable alcohol protecting groups are well known to those skilled in the art,
preferred are C1-C5 alkyl, ~-CH2-, CH3-O-CH2-, CH3-, CH3-S-CH2-, ~-CH2-O-CH2-,
tetrahydropyranyl, CH3CH(-O-C2H5)-, p-methoxybenzyl, p-methoxyphenyl, p-
nitrobenzyl, (~)3C-, (CH3)3Si-, [CH3-CH(CH3)]3Si-, ~(CH3)2Si-. These
protecting
groups are removed by means known to those skilled in the art. For example, if
Rl
containes a hydroxy substituent, it must be protected during the
transformation of
the 5-hydroxymethyl substituted oxazolidinone alcohol (III) to the 5-
aminomethyl
substituted oxazolidinone amine (VII) or the 5-acylamidomethyl substituted
oxazolidinone (VIII). If the R1 substituent contains a free primary or
secondary
amino substituent it does not have to be protected during formation of the 5-
hydroxymethyl substituted oxazolidinone alcohols (III) but must be protected
during
transformation of he 5-hydroxymethyl substituted oxazolidinone alcohols (III)
to the
corresponding 5-aminomethyl substituted oxazolidinone amines (VII) and the 5-
acylamidomethyl substituted oxazolidinones (VIII). The reason is that the
amino
group will in general undergo an undesired side reaction during one or more of
the
steps involved in the transformation of the 5-hydroxymethyl substituted
oxazolidinone alcohols (III) to the corresponding 5-acylamidomethyl
substituted
oxazolidinones (VIII). Therefore, it is preferable to protect any free amino
substituent in the R1 functionality prior to the reaction of the dihydroxy
compound
(I) or glycidol (IV) with the carbamate (IIA) or trifluoroacetamide (IIB).
Amino
protecting groups are very well known to those skilled in the art. Preferred
amino
protecting groups include:
(I) C1-C4 alkyl,
CA 02557862 1997-03-28
(II) ~-CHZ-,
(III) (~)3C-,
(IV) Ra CO- where Ra is (A) H-, (B) C1-C4 alkyl, (C) C5-Cq cycloalkyl, (D) (C1-
C5 alkyl)-O-, (E) C13C-CH2-O-, (F) H2C=CH-CHZ-O-, (G) ~-CH=CH-CH2-O-, (H) ~-
CH2-O-, (I) p-methoxyphenyl-CH2-O-, (J) p-nitrophenyl-CH2-O-, (I~ ~-O-, (L)
CH3-
CO-CH2-, (M) (CH3)3Si-O-,
(~ Rb-S02- where Rb is: (A) (C1 alkyl)-, (B) ~-, (C)p-methylphenyl- and (D)
~-CH2-. A preferred amino protecting group is benzyloxycarbonyl which can be
removed by catalytic hydrogenation as is known to those skilled in the art.
There is
nothing novel regarding the use of protecting groups in these reactions or the
nature
of the particular protecting groups. All this is well known to those skilled
in the art.
The protecting groups can be removed after the last reaction in which the
protected
substituent would be a~'ected or carried along and removed after subsequent
reactions as is known to those skilled in the art. For example, it my be
preferable to
carry the protecting group along until the final acylation step is completed,
before
removal, as is known to those skilled in the art. Optionally the R1
substituent can
be modified after the 5-acylamidomethyl substituted oxazolidinones (VIII) is
produced depending on what chemical reactions are required as is known to
those
skilled in the art.
The reaction of either dihydroxy compounds (I) or glycidol (IV) with either
the
carbamates (IIA) or trifluoroacetamides (IIB) give the same 5-hydroxymethyl
substituted oxazolidinone alcohols (III). The choice of whether to use a
dihydroxy
compound (I) or glycidol (IV) to produce a particular 5-hydroxymethyl
substituted
oxazolidinone alcohol (III) has to be made on a case by case basis. No
starting
material is preferred in all cases; there is no generally preferred way based
on
chemistry alone. The decision involves the commercial availability of the
particular
starting material, its chemical and enantiomeric purity, its cost, etc as is
known to
those skilled in the art.
One process of the present invention is the reaction of the dihydroxy
compound (I) or glycidol (IV) with the carbamate (IIA) or trifluoroacetamides
(IIB)
in the presence of lithium cation (Li+) and a base whose conjugate acid has a
pKa of
greater than about 8.
The processes requires about one molar equivalent of either the dihydroxy
compound (I) or glycidol (IV)/equivalent of carbamate (IIA) or
triffuoroacetamides
(IIB). The reaction requires a base, the nature of which is not critical so
long as it is
16
CA 02557862 1997-03-28
strong enough to deprotonate the carbamate (II). Operable bases are those
whose
conjugate acid has a pKa of greater than about 8. Preferred bases include
compounds selected from the group consisting of
alkoxy compounds of one thru seven carbon atoms,
carbonate,
methyl, sec-butyl and t-butyl carbanions,
tri(alkyl)amines where the alkyl group is from 1 thru 4 carbon atoms,
conjugate base of the carbamate (II),
DBU,
DBN,
N-methyl-piperidine,
N-methyl morpholine,
2,2,2-trichloroethoxide and
C13C-CHZ-O-; most preferred bases are where the base is alkoxy of four or
five carbon atoms. It is preferred that the four and five carbon alcohol bases
be t-
amylate or t-butoxide. Sodium or potassium bases in combination with a lithium
salt (such as lithium chloride or lithium bromide) can be used forming the
lithium
ration and base in situ.
The nature of the solvent is not critical. Operable solvents include cyclic
ethers such as THF, amides such as DMF and DMAC, amines such as
triethylamine, acetonitrile, and alcohols such as t-amyl alcohol and t-butyl
alcohol.
The choice of solvent depends on the solubility of the carbamate (IIA) or
triffuoroacetamide (IIB) as is known to those skilled in the art.
When the starting material is the dihydroxy compounds (I) it can be
beneficial to react the dihydroxy compound (I) with an cyclizing agent prior
to
contacting with the carbamate (IIA) or triffuoroacetamide (IIB). The term
"cyclizing
agent" refers to a base that cyclizes the dihydroxy compound (I) to glycidol
(I~.
Operable cyclizing agents include bases whose acid has a pka of greater than
about
7; preferred cyclizing agents are sodium, potassium or lithium butoxide,
sodium or
potassium hydroxide, potassium carbonate, DBU, lithium, sodium and potassium
amylate; most preferred is potassium t-butoxide. It is preferable to perform
the
reaction at < 100°, more preferable to perform it at < 70°, even
more preferable to
perform it at < 50° and most preferable to perform it at < 25°.
The reaction can be
performed at room temperature (about 20 to about 25°). At about
20°, the reaction
requires about 8 hr to reach completion (in DMAC). If a faster reaction is
desired,
17
CA 02557862 1997-03-28
the reaction can be run at higher temperature. As stated above,
differentiation
between primary alcohols and secondary alcohols is diffcult. In the
cyclization
reaction, a simple alcohol is formed. For instance, benzyl alcohol is formed
when a
benzyl carbonate is subjected to the cyclization conditions. Removal of this
alcohol
is necessary to the success of the alcohol to amine conversion. This is
accomplished
by crystallization using ethyl acetate/heptane (1/2). The benzyl alcohol stays
in
solution and the desired oxazolidinone alcohol is isolated as a solid.
CHA,R,T C discloses the processes of transforming the 5-hydroxymethyl
substituted oxazolidinone alcohols (III) to the corresponding 5-aminomethyl
substituted oxazolidinone amines (VII). The situation of protecting the
alcohol
andlor amino groups on the R1 functionality was discussed above. The 5
hydroxymethyl substituted oxazolidinone alcohols (III) are contacted with a
sulfonylating agent (Va Vd) of four types. These are M3-S02-C6Hn3(N02)nlCln2
Via), OL-S02-C6Hn3(N02)nlCln2]2 (Vb), 0(S02-F)2 (Vc) and O(S02-CF3)2 (Vd). M3
is a leaving group which includes CI- or Br-; it is preferred that M3 be Cl-.
The 5-
hydroxymethyl substituted oxazolidinones (III) are contacted with a
sulfonylating
agent (Va Vd) to form a oxazolidinone sulfonate (VTa VId) intermediate.
The sulfonation reaction of converting the 5-hydroxymethyl substituted
oxazolidinones (III) to the corresponding oxazolidinone sulfonates (VI) is
performed
by contacting the 5-hydrogymethyl substituted oxazolidinones (III) with at
least one
molar equivalent of the sulfonylating agent (Va Vd) in the presence of a base
in an
inert solvent at about 0°. Operable bases include triethylamine,
tributylamine,
diisopropylethylamine, DABCO, DBU, DBN, n-butyl lithium, ethyl magnesium
chloride and the equivalents thereof; preferred is triethylamine. Inert
solvents
include most organic solvents such as methylene chloride, THF, DMA, DMF, ethyl
acetate, and the equivalent thereof; preferred is methylene chloride.
The ammonolysis reaction of the conversion of the oxazolidinone sulfonates
(VI) to the corresponding 5-aminomethyl substituted oxazolidinone amines (VII)
is
performed under open or non-sealed conditions or under sealed conditions
although
it is preferred to be performed under sealed conditions.
In either case the ammonolysis reaction is carried out by contacting the
oxazolidinone sulfonates (VI) with ammonia (preferably aqueous) preferably
with a
solvent or mixture of solvents. Preferred solvents are those that dissolve
both the
oxazolidinone sulfonates (VI) and the aqueous ammonia because by dissolving
both
contact between them is insured. However, the process is also operable with
18
CA 02557862 1997-03-28
solvents that only partially dissolve the oxazolidinone sulfonates (VI), the
disadvantage
is that the reaction in general is slower. In the case of the m-
nitrobenzenesulfonates, the
preferred solvent is a mixture of acetonitrile/isopropanol or THF/isopropanol.
The
system is put under reduced pressure. The system is then closed or sealed, and
the
S ammonia (preferably aqueous ammonia) is added and heated to less than
50°, preferably
to less than 40°, preferably to about 38° (about 3 psig). At
about 38-40° the pressure is
about 0 to about 10 psig, which is well below the ceiling pressure rating of
general
purpose reactors. Under these conditions, at about 60°, the psig is
about 20. It is
preferred that the ammonolysis reaction be performed at a pressure of about 0
to about 20
psig, preferably at about 0 to about S psig and at about 60° or less.
Alternatively, the
reaction is performed in an open system at reflux. In this case the
temperature will be
slightly lower and the reaction will require slightly longer to reach
completion. The
ammonia can be either aqueous, alcoholic or anhydrous; however, aqueous
ammonia is
preferred.
Alternatively, the contacting with aqueous ammonia can be performed in the
presence of an aromatic aldehyde (IX, Ar-CHO), preferably solicylaldehyde. The
S-
aminomethyl substituted oxazolidinone amines (VII) and the aldehyde (IX) form
a Schiff
base of the formula (oxazolidinone-N=CH-Ar) which is then hydrolyzed with
aqueous
acid, as is known to those skilled in the art, to give the desired 5-
aminomethyl substituted
oxazolidinone amines (VII). The aromatic aldehyde (IX) is useful in
suppressing dimer
formation. In a preferred embodiment, the aromatic aldehyde Ar-CHO comprises a
molecule where the Ar is a phenyl which is optionally substituted with a
substituent
selected from F, Cl, Br, C,-CS alkyl, HO, OZN, CH3-O and CZHS-O.
The 5-aminomethyl substituted oxazolidinone amines (VII) are acylated by
known means such as acyl halides or acyl anhydrides to form the corresponding
5-
acylamidomethyl substituted oxazolidinone (VIII), see CHART D. Any alcohol or
amino
protecting groups must be removed after the S-acylamidomethyl substituted
oxazolidinones (VIII) are produced. However, they can be removed earlier in
the
reaction sequence depending on the particular substituents in question as is
known to
those skilled in the art.
The S-acylamidomethyl substituted oxazolidinones (VIII) are known to be
antibacterial pharmaceutical agents. RZ is selected from the group consisting
of -H, C,-
C,2 alkyl optionally substituted with one or more halogens, (C3-C7)cyclo(CS
C9)alkyl or -
O-RZa where R2a is C,-C6 alkyl. It is preferred that R2 is C, alkyl.
DEFINITIONS AND CONVENTIONS
The definitions and explanations below are for the terms as used throughout
this
entire document including both the specification and the claims.
19
CA 02557862 1997-03-28
I. CONVENTIONS FOR FORMULAS AND DEFINITIONS OF VARIABLES
The chemical formulas representing various compounds or molecular fragme-
nts in the specification and claims may contain variable substituents in
addition to
expressly defined structural features. These variable substituents are
identified by
a letter or a letter followed by a numerical subscript, for example, "Z1" or
"Ri" where
"i" is an integer. These variable substituents are either monovalent or
bivalent, that
is, they represent a group attached to the formula by one or two chemical
bonds.
For example, a group Z1 would represent a bivalent variable if attached to the
formula CH3-C(=Z1)H. Groups Ri and R~ would represent monovalent variable
substituents if attached to the formula CH3-CH2-C(Ri)(R~)-H. When chemical
formulas are drawn in a linear fashion, such as those above, variable
substituents
contained in parentheses are bonded to the atom immediately to the left of the
variable substituent enclosed in parenthesis. When two or more consecutive
variable substituents are enclosed in parentheses, each of the consecutive
variable
substituents is bonded to the immediately preceding atom to the left which is
not
enclosed in parentheses. Thus, in the formula above, both Ri and R~ are bonded
to
the preceding carbon atom. Also, for any molecule with an established system
of
carbon atom numbering, such as steroids, these carbon atoms are designated as
Ci,
where "i" is the integer corresponding to the carbon atom number. For example,
C6
represents the 6 position or carbon atom number in the steroid nucleus as
tradition-
ally designated by those skilled in the art of steroid chemistry. Likewise the
term
"R6" represents a variable substituent (either monovalent or bivalent) at the
C6
position.
Chemical formulas or portions thereof drawn in a linear fashion represent
atoms in a linear chain. The symbol "" in general represents a bond between
two
atoms in the chain. Thus CH3-O-CH2-CH(Ri)-CH3 represents a 2-substituted-1-
methoxypropane compound. In a similar fashion, the symbol "_" represents a
double
bond, e.g., CH2=C(Ri)-O-CH3, and the symbol "-" represents a triple bond,
e.g.,
HC--__C-CH(Ri)-CH2-CH3. Carbonyl groups are represented in either one of two
ways: -CO- or -C(=O)-, with the former being preferred for simplicity.
Chemical formulas of cyclic (ring) compounds or molecular fragments can be
represented in a linear fashion. Thus, the compound 4-chloro-2-methylpyridine
can
be represented in linear fashion by N*=C(CH3)-CH=CCl-CH=C*H with the
convention that the atoms marked with an asterisk (*) are bonded to each other
resulting in the formation of a ring. Likewise, the cyclic molecular fragment,
4-
CA 02557862 1997-03-28
(ethyl)-1-piperazinyl can be represented by -N*-(CH2)2-N(C2H5)-CH2-C*H2.
A rigid cyclic (ring) structure for any compounds herein defines an
orientation
with respect to the plane of the ring for substituents attached to each carbon
atom of
the rigid cyclic compound. For saturated compounds which have two substituents
attached to a carbon atom which is part of a cyclic system, -C(Xl)(X2)- the
two sub-
stituents may be in either an axial or equatorial position relative to the
ring and
may change between axial/equatorial. However, the position of the two
substituents
relative to the ring and each other remains fixed. While either substituent at
times
may lie in the plane of the ring (equatorial) rather than above or below the
plane
(axial), one substituent is always above the other. In chemical structural
formulas
depicting such compounds, a substituent (X1) which is "below" another
substituent
(X2) will be identified as being in the alpha (a) configuration and is
identified by a
broken, dashed or dotted line attachment to the carbon atom, i.e., by the
symbol "- -
-" or "...". The corresponding substituent attached "above" (X2) the other
(X1) is
identified as being in the beta (!3) configuration and is indicated by an
unbroken line
attachment to the carbon atom.
When a variable substituent is bivalent, the valences may be taken together
or separately or both in the definition of the variable. For example, a
variable Ri
attached to a carbon atom as -C(=Ri)- might be bivalent and be defined as oxo
or
keto (thus forming a carbonyl group (-CO-) or as two separately attached
monovalent
variable substituents a-Ri ~ and 13-Ri-k. When a bivalent variable, Ri, is
defined to
consist of two monovalent variable substituents, the convention used to define
the
bivalent variable is of the form "a-Ri x:13-Ri-k' or some variant thereof. In
such a
case both a-Ri ~ and 13-Ri-k are attached to the carbon atom to give -C(a-Ri ~
)(13-Ri-k)-
. For example, when the bivalent variable R6, -C(=R6)- is defined to consist
of two
monovalent variable substituents, the two monovalent variable substituents are
a-
R6-1:J3-R6-2, .... a-R6-9:13-Rs-lp, etc, giving -C(a-R6-1)(!3-R6-2)-, .... -
C(a-R6-9)(13-R6-10)-,
etc. Likewise, for the bivalent variable Rll, -C(=Rll)-, two monovalent
variable
substituents are a-R11-lv-R11-2~ For a ring substituent for which separate a
and 13
orientations do not exist (e.g. due to the presence of a carbon carbon double
bond in
the ring), and for a substituent bonded to a carbon atom which is not part of
a ring
the above convention is still used, but the a and 13 designations are omitted.
Just as a bivalent variable may be defined as two separate monovalent
variable substituents, two separate monovalent variable substituents may be
defined
to be taken together to form a bivalent variable. For example, in the formula
21
CA 02557862 1997-03-28
-C1(Ri)H-C2(R~)H- (C1 and CZ define arbitrarily a first and second carbon
atom,
respectively) Ri and R~ may be defined to be taken together to form (1) a
second
bond between C1 and C2 or (2) a bivalent group such as oxa (-O-) and the
formula
thereby describes an epoxide. When Ri and R~ are taken together to form a more
complex entity, such as the group -X-Y-, then the orientation of the entity is
such
that C1 in the above formula is bonded to X and C2 is bonded to Y. Thus, by
convention the designation "... Ri and R~ are taken together to form -CH2-CH2-
0-
CO- ..." means a lactone in which the carbonyl is bonded to C2. However, when
designated "... R~ and Ri are taken together to form -CO-O-CH2-CHZ-the
convention
means a lactone in which the carbonyl is bonded to C1.
The carbon atom content of variable substituents is indicated in one of two
ways. The first method uses a prefix to the entire name of the variable such
as "C1-
C4", where both "1" and "4" are integers representing the minimum and maximum
number of carbon atoms in the variable. The prefix is separated from the
variable
by a space. For example, "C1-C4 alkyl" represents alkyl of 1 through 4 carbon
atoms, (including isomeric forms thereof unless an express indication to the
contrary
is given). Whenever this single prefix is given, the prefix indicates the
entire carbon
atom content of the variable being defined. Thus C2-C4 alkoxycarbonyl
describes a
group CH3-(CH2)n-O-CO- where n is zero, one or two. By the second method the
carbon atom content of only each portion of the definition is indicated
separately by
enclosing the "Ci-C~" designation in parentheses and placing it immediately
(no
intervening space) before the portion of the definition being defined. By this
optional convention (C1-C3)alkoxycarbonyl has the same meaning as C2-C4 alkoxy-
carbonyl because the "C 1-C3" refers only to the carbon atom content of the
alkoxy
group. Similarly while both CZ-C6 alkoxyalkyl and (C1-C3)alkoxy(C1-C3)alkyl
define
alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions
dii~'er
since the former definition allows either the alkoxy or alkyl portion alone to
contain
4 or 5 carbon atoms while the latter definition limits either of these groups
to 3
carbon atoms.
When the claims contain a fairly complex (cyclic) substituent, at the end of
the phrase naming/designating that particular substituent will be a notation
in
(parentheses) which will correspond to the same name/designation in one of the
CHARTS which will also set forth the chemical structural formula of that
particular
substituent.
22
CA 02557862 1997-03-28
II. DEFINITIONS
All temperatures are in degrees Centigrade.
TLC refers to thin-layer chromatography.
THF refers to tetrahydrofuran.
DMF refers to dimethylformamide.
DBU refers to 1,8-diazabicyclo[5.4.0]undec-7-ene.
DBN refers to 1,5-diazabicyclo[4.3.0]non-5-ene.
DABCO refers to 1,4-diazabicyclo[2.2.2]octane.
DMA refers to dimethylacetamide.
Saline refers to an aqueous saturated sodium chloride solution.
Chromatography (column and flash chromatography) refers to
purification/separation of compounds expressed as (support, eluent). It is
understood
that the appropriate fractions are pooled and concentrated to give the desired
compound(s).
IR refers to infrared spectroscopy.
CMR refers to 13C magnetic resonance spectroscopy, chemical shifts are
reported in ppm (S) downfield from TMS.
NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical
shifts are reported in ppm (8) downfield fmm tetramethylsilane.
-~ refers to phenyl (C6H5).
[a]D~ refers to the angle of rotation of plane polarized light (specific
optical
rotation) at 25° with the sodium D line (589A).
MS refers to mass spectrometry expressed as m/e, m/z or mass/charge unit.
[M + H]+ refers to the positive ion of a parent plus a hydrogen atom. EI
refers to
electron impact. CI refers to chemical ionization. FAB refers to fast atom
bombardment.
HRMS refers to high resolution mass spectrometry.
Pharmaceutically acceptable refers to those properties and/or substances
which are acceptable to the patient from a pharmacological/toxicological point
of
view and to the manufacturing pharmaceutical chemist from a physical/chemical
point of view regarding composition, formulation, stability, patient
acceptance and
bioavailability.
When solvent pairs are used, the ratios of solvents used are volume/volume
(v/v).
When the solubility of a solid in a solvent is used the ratio of the solid to
the
23
CA 02557862 1997-03-28
solvent is weight/volume (wt/v).
rITVNNNN-NN-N refers to Chemical Abstracts Service (CAS, Columbus, Ohio)
registry numbers where each "N" is an integer from 0 thru 9, but deleting
leading
zeros in the 6-digit portion of the number. Registry numbers are assigned to a
particular chemical compound by CAS criteria, provided that the compound has
been
found to exist and it has been characterized in some way. Compounds published
from approximately 1967 to the present are registered publicly and the
registry
number is the key to finding references in the CAS data base for such a
registered
compound. The CAS data base is publicly available from several database
vendors
such as STN International, System Development Corporation (SDC) Orbit Search
Service, Lockheed Dialog, Bibliographic Retrieval Systems, Questrel, etc. CAS
registry numbers are included in the EXAMPLES for some of the compounds which
have been registered.
"psig" refers to "gauge pressure" equal to pressure (in psi) minus 1
atmosphere (14.7 psi).
EXAMPLES
Without further elaboration, it is believed that one skilled in the art can,
using the preceding description, practice the present invention to its fullest
extent.
The following detailed examples describe how to prepare the various compounds
and/or perform the various processes of the invention and are to be construed
as
merely illustrative, and not limitations of the preceding disclosure in any
way
whatsoever. Those skilled in the art will promptly recognize appropriate
variations
from the procedures both as to reactants and as to reaction conditions and
techniques.
EXAMPLE 1 (R)-[N-3-[3-Fluoro-4-[N-1-(4-caxbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol (III)
A mixture of N-carbobenzoxy-3-fluoro-4-(N-carbobenzoxypiperazinyl)aniline
(II, J. Med. Chem., 39(3), 673 (1996)), 100 g of 98.4% pure material, 0.2133
moles) in
DMAC (300 ml) is cooled to 0°. In a separate flask, a mixture of t-amyl
alcohol (75
ml, 60.37 g, 0.685 moles, 3.23 eq) and heptane (75 ml) is cooled to -
10° and treated
with n-butyllithium in heptane (290 ml, 203 g of 14.4% wtlv solution,
containing
29.2 g or 0.456 moles = 2/15 eq of n-butyllithium), keeping the temperature
below
10°. The lithium t-amylate mixture is then added to the N-carbobenzoxy-
3-fluoro-4-
(N-carbobenzoxypiperazinyl)aniline (II) keeping the temperature below
10°.
Neat S-(+)-3-chloro-1,2-propanediol (I, CAS #60827-45-4, 22 ml, 29.1 g, 0.263
24
CA 02557862 1997-03-28
moles, 1.24 eq) is then added, rinsing with a small amount of heptane. The
reaction
mixture is then stirred at 20-25° and monitored by TLC
(methanoUmethylene
chloride; 5/95) until the reaction is complete. The reaction mixture is then
added to
a mixture of acetic acid (40 ml, 42.0 g, 0.699 moles, 3.29 eq) in methanol
(?00 ml)
and water (700 ml). The slurry formed is stirred at 20-25° for 30 min,
cooled to 0°,
stirred at 0° for 30 min, and filtered. The cake is washed with
methanol/water
(50/50) and dried under reduced pressure to give the title compound, TLC
(methylene chloridelmethanol, 95/5) Rf = 0.43.
EXAMPLE 2 (R)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl)phenyl]-2-
oxo-5-oxazolidinyl]methanol (III)
t-Amyl alcohol (0.967g, 10.97mmo1, 2.571 eq) is cooled to -IO°. Butyl
lithium
(4.3 ml, 2.5 M in hexanes, 10.8 mmol, 2.5 eq) is added with agitation while
maintaining the temperature at less than 5°.
N-Carbobenzoxy-3-fluoro-4-(N-carbobenzoxypiperazinyl)aniline (II, 1.9780 g,
4.267 mmol, 1.000 eq) and dimethylacetamide (6.2 ml) are mixed, agitated and
cooled to -25° to give a thin slurry. The lithium t-amylate mixture is
then added to
the N-benzyloxycarbonyl-3-fluoro-4-((4-benzyloxycarbonyl)-1-
piperazinyl)aniline (II)
mixture while maintaining less than -20°. The resultant mixture is
warmed to 0°
and S-(+)-3-chloro-l,2-propanediol (I, 0.5672 g, 5.131 mmol, 1.20 eq) is
added. The
resultant mixture is warmed to 21° and stirred for 7.5 hrs.
The reaction mixture is added to a methanol (28 ml) and glacial acetic acid
(0.73 ml,
12.75 mmol) mixture at 20-22°. The resulting slurry is then cooled to -
30° and the
product collected by vacuum filtration and washed with -30° methanol.
The solids
are dried in a stream of nitrogen to give the title compound, TLC (eluant
chloroform/methanol, 90/10), Rp = 0.67; CMR (CDC13) 43.91, 46.39, 50.58,
62.60,
67.29, 72.89, 107.21, 107.56, 113.85, 119.36, 127.92, 128.09, 128.52, 133.51,
133.65,
136.05, 136.17, 136.57, 153.91, 154.80, 155.25 and 157.17 b; NMR (CDC13) ?.43,
7.31-7.37, 7.09, 6.88, 5.15, 4.67-4.90, 3.89-3.99, 3.6?-3.74, 3.66, 3.25 and
2.98 8;
MS (CI, m/e) = 430 (100%, P+1).
EXAMPLE 3 (R,)-[N-3-(3-Fluoro-4-(4-morpholinylphenyl)-2-oxo-5-
oxazolidinyl]methanol (III)
Tetrahydrofuran (3.0 ml) and t-amyl alcohol (0.66 ml, 6.03 mmol, 2.00 eq) are
mixed. Butyl lithium ( 1.8 ml, 2.5 M in hexanes, 4.55 mmol, 1.5 eq) is added
with
agitation and while maintaining less than 2.5°.
N-Carbobenzoxy-3-fluoro-4-morpholinylaniline (II, J. Med. Chem., 39(3), 673
CA 02557862 1997-03-28
(1996), 0.9942 g, 3.009 mmol, 1.000 eq) and tetrahydrofuran (3.5 ml) are
mixture
agitated and cooled. The lithium t-amylate mixture is then added to the
carbamate
(II) mixture while maintaining the temperature less than 8° and rinsed
in with
tetrahydrofuran (1 ml).
Tetrahydrofuran (3.2 ml) and S-(+)-3-chloro-1,2-propanediol (I, 0.299 ml, 3.58
mmol, 1.19 eq) are mixed. The mixture is cooled to -16° and potassium t-
butoxide
(3.2 ml, 1.0 M in tetrahydrofuran, 3.2 mmol, 1.07 eq) is added while
maintaining the
temperature at less than -10°. The resulting slurry is stirred at -14
to 0° for 1 hr
then added to the lithium anion mixture while maintaining both mixtures at
0°,
then rinsed in with THF (2 ml). The resultant slurry is stirred at 20-
23° for 2 hr
then cooled to 6° and a mixture of citric acid monohydrate (0.4459 g,
2.122 mmol,
0.705 eq) in water (10 ml) is added. The resultant liquid phases are separated
and
the lower aqueous phase is washed with ethyl acetate (12 ml). The organic
layers
are combined and solvent is removed under reduced pressure until a net weight
of
9.73 g remains. Heptane ( 10 ml) and water (5 ml) are added and solvent is
removed
by reduced pressure until a total volume of 5 ml remains. The precipitated
product
is collected by vacuum filtration and washed with water (7 ml). The solids are
dried
in a stream of nitrogen to give the title compound, TLC (chloroform/methanol,
95/5)
Rf = 0.23; CMR (CDCl3) 46.42, 51.01, 62.58, 73.07, 107.29, 107.64, 113.94,
118.80,
118.85, 128.28, 128.61, 133.15, 133.29, 136.26, 136.38, 153.82, 154.92 and
157.08 8;
NMR (CDC13) 7.42, 7.32-7.37, 7.10, 4.67-4.75, 3.90-4.00, 3.86, 3.70-3.73, 3.44
and
3.03 8; MS (EI, m/e) = 296.
Alternatively, the crude product can be extracted with methylene chloride.
The solvent is removed under reduced pressure. The solids are redissolved in
hot
ethyl acetate, heptane is added, the mixture is cooled and the title compound
is
recovered.
EXAMPLE 4 (R)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol (III)
A solution of t-amyl alcohol (75 ml, 60.3 g, 0.68 m) and heptane (75 ml) is
stirred and cooled to -10°. The mixture is treated with n-butyl lithium
in heptane
(1.6 M, 0.46 m, 290 ml) over a 30 min period while maintaining a temp <
10°. After
30 min, the mixture of lithium t-amylate is added to a mixture of N-
carbobenzoxy-3-
fluoro-4-(N-carbobenzoxypiperazinyl)aniline (II, 100 g, 0.22 m) and
dimethylacetamide (300 ml) at 0° while maintaining a temp < 10°.
The mixture is
stirred 30 min, then treated with S-(+)-3-chloro-1,2-propanediol (I, 22 ml,
0.26 m).
26
CA 02557862 1997-03-28
The cooling is removed, and the mixture is allowed to warm to 20-25°.
The reaction
is monitored by TLC and is judged complete after about 8 hr. The reaction
mixture
is poured into a mixture of methanol (700 ml), water (700 ml) and acetic acid
(40 ml)
and stirred for 30 min at 20-25°, then stirred for 30 min with cooling
to 0°. The
mixture is filtered, washed with aqueous methanol (50/50) and dried under
reduced
pressure at 45° to give the title compound, TLC (silica gel;
methanol/methylene
chloride, 5/95) Rf = 0.5. (90.3% yield).
EXAMPLE 5 3-Nitrobenzenesulfonate ester (R)-[N-3-[3-fluoro-4-(N-1-(4-
carbobenzoxy~iperazinyl]-phenyl]-2-oxo-5-
oxazolidinyl]methanol (VI)
A mixture of (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol (III, EXAMPLE 1, 43 g, 0.1 m) and methylene
chloride
(500 ml) is treated with triethylamine (32 ml, 0.23 m) and cooled to -
5°. To this
mixture is added a mixture of 3-nitrobenzenesulfonyl chloride (CAS # 121-51-7,
32 g,
0.14 ml) in methylene chloride (60 ml) while maintaining the temp < 10°
over a 1 hr
period. The reaction is monitored by TLC and judged complete after 45 min. The
mixture is diluted with methylene chloride (500 ml) and then washed with water
(2
x 600 ml). The organic phase is then washed with hydrochloric acid (1N, 400
ml)
and concentrated to a thick residue. The residue is diluted with methanol (200
mQ)
and stirred for 1.5 hr. The solids are filtered, washed with methanol and
dried
under reduced pressure at 40° overnight to give the title compound, TLC
(silica gel;
methanol/methylene chloride, 5/95) R f = 0.75.
EXAMPLE 6 (SAN-[[3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]-phenyl]-
2-oxo-5-oxazolidinyl]methyl]acetamide (VII)
A slurry of 3-nitrobenzenesulfonate ester (R)-[N-3-[3-fluoro-4-(N-1-(4-
carbobenzoxy)piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methanol (VI, EXAMPLE
5,
50 g, 0.081 ml), isopropanol (250 ml), acetonitrile (400 ml) and aqueous
ammonium
hydroxide (29% ammonia by wt, 500 ml) is heated at 40° for 3.5 hr. The
mixture is
then treated with more aqueous ammonia (100 ml) and stirred for 20 hr. The
reaction is monitored by TLC and judged complete at this time. The mixture is
concentrated under reduced pressure with heat and suspended in methylene
chloride/water (1250 m1/750 ml). The phases are separated and the organic
phase
concentrated to give a residue.
The residue is dissolved in methylene chloride (2 1) and treated with
triethylamine (20 ml, 0.14 m). The mixture is then treated with acetic
anhydride
27
CA 02557862 1997-03-28
(10 ml, 0.11 m) at 20-25° over 10 min. The acetylation is monitored by
TLC and
judged complete after 15 min. The organic mixture is washed with water (2 x
400
mQ) then concentrated to a solid. The solids are recrystallized from ethanol
(400
mQ), filtered and dried under reduced pessure to give the title compound, TLC
(silica
gel; methanol/methylene chloride, 5/95) Rf = 0.6.
EXAMPLE 7 (S)-N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-
oxazolidinyl]methyl]acetamide hydrochloride (intermediate)
A mixture of (S)-N-[[3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]-phenyl]-2-
oxo-5-oxazolidinyl]methyl]acetamide (VII, EXAMPLE 6, 35 kg, 74.5 moles),
palladium on carbon (5%, 10 kg, 50% water wet), methanol (550 1) and
tetrahydrofuran (250 1) is agitated at 22 to 42° under a 42-50 psi
hydrogen
atmosphere. After 31 hours TLC analysis indicated complete reaction and the
hydrogen atmosphere was replaced with nitrogen. The catalyst is removed by
filtration and the filtrate concentrated under vacuum to 100 1. To the
resulting
mixture, cooled to 2°, is added methanol (50 1) then a mixture of
methanol (100 1)
and acetyl chloride (6.04 kg, 77 moles) at -2° to 6°. The
resulting mixture is stirred
90 minutes then concentrated under vacuum to 60 1, diluted with acetone (100
1) and
concentrated further to 100 1. The resulting slurry is diluted with acetone
(200 1)
and stirred 15 hr at 16°. The solids are collected on a filter, washed
with acetone
(50 1) and dried under reduced pressure at 20-25° to give the desired
product. It is
dissolved in methanol (56 1) at 53°, diluted with acetone (1501),
stirred 30 minutes
at 48° then cooled to 15° and stirred 18 hr. The solids are
collected on a filter,
washed with acetone (50 1) and dried under reduced pressure at 20-25°
to give the
title compound, NMR (CDC13) 7.56-7.45, 7.31, 7.12-6.86, 4.79, 4.09-4.0, 3.81,
3.62,
3.40-3.11 and 2.01 b.
EXAMPLE 8 (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-
oxo-5-oxazolidinyl]methyl]-acetamide sesquihydrate (VIII)
To a stirred mixture of (S)-N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5
oxazolidinyl]methyl]acetamide hydrochloride (EXAMPLE 7, 16.2 kg, 43.5 moles),
tetrahydrofuran (205 kg) and triethylamine (10.1 kg, 100 moles) is added
acetoxyacetyl chloride (6.5 kg, 47.8 moles) in tetrahydrofuran (11.1 kg) over
35
minutes keeping the temperature at 22-23°. After 40 minutes, at which
time TLC
and HPLC analysis indicated complete formation of the acetoxyacetamide
intermediate, the mixture is concentrated under reduced pressure to 301,
diluted
with methanol (100 1) and concentrated to 30 1. To the residue is added
methanol
28
CA 02557862 1997-03-28
(251) and an aqueous solution of potassium carbonate (5.6 kg in 561). The
resulting
mixture is stirred 20 hr at 22-25° at which time TLC and HPLC analysis
indicates
the reaction is complete. The pH is adjusted to 7-7.5 with hydrochloric acid
(4 N,
14.3 1). The mixture is stirred 18 hr at 15-22° then 3 hrs at 2-
5°. The solids are
collected on a filter, washed with water (68 1) and dried at 20-25°
with recycled
nitrogen to give the desired product. The crude product is dissolved in water
(225 1)
at 60-70°, clarified through a 0.6 micron filter, diluted with water
rinse (55 1) and
stirred 17 hrs. at 15°. The solids are collected on a filter, washed
with water at 15°
and dried at 45° with recycled nitrogen to a water content of 0.33%.
These solids
are dissolved in a solution of ethyl acetate (143 1), methanol (65 1) and
water (1.95 1)
at 60-65°. The solution is cooled to 15-25° and stirred 16 hrs
for crystallization. The
solids are collected on a filter, washed with ethyl acetate (75 1) and dried
with 45°
nitrogen to give the desired product. The product is recrystallized two more
times
from water ( 147 1 then 133 1) at 60-70°, clarified each time through a
0.6 micron
filter and rinsed with water (40 l and 30 1). The solids are dried on the
filter at 30°
with recycled nitrogen to give, after deagglomeration through a mill, the
title
compound as the sesquihydrate (6.45% water), TLC (silica gel;
methanoUmethylene
chloride, 5/95) Rf = 0.45; [a]D = -20° (c = 1.0, ethanol).
EXAMPLE 9 3-Nitrobenzenesulfonate ester (R)-[N-3-[3-fluoro-4-(N-1-(4-
carbobenzoxy)piperazinyl]-phenyl]-2-oxo-5-
oxazolidinyl]methanol (VI)
To a slurry of (R)-[IV-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-
2-
oxo-5-oxazolidinyl]methanol (III, EXAMPLE 1, 5.086 g, 11.86 mmol) in methylene
chloride (50 mL) and triethylamine (2.0 mL, 14.38 mmol) at 0° is added
dropwise
over 6 minutes a solution of 3-nitrobenzene sulfonyl chloride (~ in methylene
chloride (0.356M, 33.4 mL, 11.89 mmol). After stirring for 3.25 hrs, an
additional
3.4 mL ( 1.21 mmol) of the 0.356 M solution of 3-nitrobenzene sulfonyl
chloride (~ is
added. After stirring for 1.75 hrs, hydrochloric acid ( 1N, 50 mL) is added.
The
phases are separated and the aqueous phase is extracted with methylene
chloride.
The combined organic phases are washed with saline, dried over magnesium
sulfate
and concentrated. The concentrate is crystallized from hot methylene
chlorideJmethanol to give the title compound, mp = 155-157°; NMR
(CDC13, 400
MHz) 8.72, 8.51, 8.23, 7.81, 7.35, 7.01, 6.91, 5.17, 4.85, 4.44, 4.39, 4.09,
3.85, 3.68
and 3.018; CMR (CDC13, 100 Mliz) 44.26, 46.81, 50.91, 67.64, 69.54, 69.91,
107.85,
114.32, 119.85, 123.55, 128.30, 128.47, 128.91, 129.15, 131.51, 133.71,
136.99,
29
CA 02557862 1997-03-28
137.70, 148.71, 153.62, 155.57 and 155.88 8; IR (mineral oil mull) 1744, 1703,
1528,
1520, 1367, 1347 and 1192 cm 1; MS (EI, M/Z) 614, 411, 107, 91, 79, 65 and 56;
[a]D
- -78° (c = 0.9812, CHC13); TLC (ethyl acetate/hexane, 3/1) Rp = 0.43.
EXAMPLE 10 2-nitrobenzenesulfonate ester (R)-[N-3-[3-Fluoro-4-(N-1-(4-
carbobenzoxy)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methanol
Following the general procedure of EXAMPLE 5 (for the 3-
nitrobenzenesulfonyl ester, (VI)) and making non-critical variations, (R)-[N-3-
[3-
fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-oxo-5-
oxazolidinyl]methanol
(III, EXAMPLE 1, 1.106 g, 2.578 mmol) is treated with triethyl amine (0.54 mL,
3.882 mmol) and commercial grade 2-nitrobenzenesulfonyl chloride (V, 679 mg,
3.064
mmol) to give the title compound, NMR (CDC13, 400 MHz) 8.15, 7.82, 7.37, 7.06,
6.94, 5.17, 4,89, 4.59, 4.50, 4.10, 3.98, 3.69 and 3.03 b; IR (mineral oil
mull) 1757,
1697, 1517, 1445, 1423, 1376, 1237 and 1188 cni 1; MS (EI, M/Z; rel.
abundance):
614 (18.3, M+), 91 (100), 69 (23.8) and 56 (52.9); TLC (ethyl acetatelhexane,
3/1) Rf =
0.31.
EXAMPLE 11 2,4-dinitrobenzenesulfonate ester (R)-[N-3-[3-Fluoro-4-[N-1-(4-
carbobenzoxy)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methanol
Following the general procedure of EXAMPLE 5 (for the 3-
nitrobenzenesulfonyl ester) and making non-critical variations (R,)-[N-3-[3-
Fluoro-4-
[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methanol (III,
EXAMPLE 1, 1.094 g, 2.550 mmol) is treated with triethyl amine (0.55 mL, 3.950
mmol) and commercial grade 2,4-dinitrobenzenesulfonyl chloride (833 mg, 3.124
mmol) to give the title compound, NMR (CDC13, 400 MHz) 8.59, 8.38, 7.35, 7.02,
5.17, 4.88, 4.74, 4.58, 4.10, 3.98, 3.71, and 3.05 b; IR, (mineral oil mull)
1756, 1697,
1554, 1541, 1517, 1351, 1237 and 1189 cnz 1; MS (FAB, M/Z, rel. abundance) 660
(21.3, [M+H]+), 659 (24.2, M+), 102 (76.5) and 91 (100); TLC (ethyl
acetate/hexane,
3/1) Rf = 0.41.
EXAMPLE 12 (R)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol 4-chlorobenzenesulfonate ester (VI)
To a slurry of (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol (III, EXAMPLE l, 3.450 g, 8.034 mmol) in methylene
chloride (40 ml) and triethylamine (2.55 ml, 18.3 mmol) at -12° is
added 4-
chlorobenzenesulfonyl chloride (V, Aldrich Chemical Co.- commercial, 2.298 g,
10.88
CA 02557862 1997-03-28
mmol) as a solid all at once. The mixture is stirred in a 0° bath for
2.5 hrs then
washed with water (2 X 35 ml), and 1N hydrochloric acid (35 ml). The organic
extracts are concentrated to 20 ml total volume and methanol (50 ml) is added.
The
precipitate is collected by vacuum filtration, washed with methanol, dried and
redissolved in methylene chloride (55 ml). The mixture is concentrated to a
slurry
of 32 g weight and methanol (11 ml) is added. The precipitate is collected by
vacuum filtration, washed with methanol and dried. The solids are then
dissolved
in methylene chloride (58 ml) and column chromatographed (silica column, 93 g
40-
63 u; eluted with 450 ml each of following ethyl acetate/cyclohexane mixtures
25/75;
35/65; 45155; 55/45; collect last 50% of eluent). The collected eluent is
concentrated
to 200 ml and 200 ml heptane is added. The precipitate is collected by vacuum
filtration and dried to give the title compound; TLC (silica gel; methanol/
chloroform
5/95) Rf = 0.53; MS (FAB, MlZ) = 604.7 (100%, [P+H]+); NMR (DMSO-ds, 300 MHz)
7.93, 6.7, 7.75, 7.48-7.32, 7.12-7.03, 5.12, 4.93-4.92, 4.40, 4.09, 3.69, 3.57
and 2.96 8;
CMR (DMSO-ds, 75 MHz) 43.51, 45.84, 50.22, 66.33, 69.75, 70.75, 106.63,
114.08,
119.83, 127.59, 127.87, 128.43, 129.62, 130.00, 133.31, 133.63, 135.52,
136.84,
139.63, 153.54, 154.40 and 154.62 s.
EXAMPLE 13 (R)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol 2,5-dichlombenzenesulfonate ester
(VI)
To a slurry of (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol (III, EXAMPLE 1, 3.439 g, 8.008 mmol) in methylene
chloride (40 ml) and triethylamine (2.55 ml, 18.3 mmol) at -8° is added
2,5-
dichlorobenzenesulfonyl chloride (V, Aldrich Chemical Co. - commercial, 2.675
g,
10.90 mmol) as a solid all at once. The mixture is stirred in a 0° bath
for 2.5 hrs
then washed with water (2 X 35 ml), and 1N hydrochloric acid (35 ml). The
organic
extracts are then concentrated to 12.0 g which is column chromatographed
(silican
column, 108 g, 40-63 u; eluted with 450 ml each of following ethyl
acetate%yclohexane mixtures 10/90, 20/80, 30/70, 40/60 and 60/40 collecting
the last
20% of eluent). The collected eluent is concentrated and 300 ml methanol is
added.
The precipitate is collected by vacuum filtration, washed with methanol and
dried to
give the title compound, TLC (silica gel; methanol/chloroform 5/95) Rf = 0.66;
MS
(FAB, M/Z) = 638.6 (100%, [P+H]+); NMR (CDCl3, 300 MHz) 8.04, 7.57-7.32, 7.06,
6.91, 5.16, 4.89-4.47, 4.42, 4.08, 3.93, 3.67 and 3.018; CMR (CDC13, 75 MHz)
43.93,
45.51, 50.56, 67.26, 69.16, 69.46, 107.55, 113.98, 119.41, 127.92, 128.10,
128.54,
31
CA 02557862 1997-03-28
131.21, 131.46, 132.97, 133.44, 133.50, 134.68, 135.15, 136.45, 136.61,
153.36, 155.22
and 155.53 8.
EXAMPLE 14 (R)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol 4-nitrobenzenesulfonate ester (VI)
To a slurry of (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxa.zolidinyl]methanol (III, EXAMPLE 1, 3.437 g, 8.003 mmol) and 4-
nitrobenzenesulfonyl chloride (V, 75% pure technical material, Aldrich
Chemical Co.-
commercial, 3.077 g, 10.41 mmol) in methylene chloride (32 ml) at 0° is
added
triethylamine (2.23 ml, 16.0 mmol). The mixture is stirred in a 0° bath
for 1 hr then
water ( 1 ml) is added and the mixture stirred at 20-25° for 30 min.
Methylene
chloride (75 ml) is added and the mixture washed with hydrochloric acid (5%,
50
ml), then sodium bicarbonate (5%, 50 ml) and dried on magnesium sulfate. The
organic extracts are then concentrated and the concentrate is taken up in
boiling
ethyl acetate%yclohexane (1/1, 10 ml) and column chromatographed (silica gel,
4 cm
X 6", 40-63 u; eluting with about 400 ml each of following ethyl
acetatelcyclohexane
mixtures 20/80, 30/70, 40/60, 50/50, 60/40 and 70:30 collecting the last
approximate
45% of eluent). The appropriate fractions are combined and concentrated to a
solid
which is dissolved in 70 ml methylene chloride and 50 ml ethyl acetate. The
mixture is concentrated to 50 ml twice and cyclohexane (50 ml) is added after
each
concentration. The precipitate is collected by vacuum filtration, washed with
cyclohexane and dried to give the title compound, TLC (silica gel; ethyl
acetatelcyclohexane 60/40) Rf = 0.37; NMR (CDC13, 300 MHz) 8.36, 8.07, 7.38-
7.29,
7.03, 6.89, 5.15, 4.86-4.80, 4.39, 4.07, 3.80, 3.67 and 3.00 b; CMR (CDC13, 75
MHz)
43.85, 46.34, 50.45, 67.20, 69.17, 69.57, 107.64, 113.88, 119.34, 124.63,
127.85,
128.05, 128.49, 129.26, 132.67, 136.48, 136.57, 140.75, 150.95, 153.29, 155.14
and
155.40 8.
EXAMPLE 15 (S)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methylamine (VII)
Under nitrogen at 40° 3-nitrobenzenesulfonate ester (R)-(N-3-(3-fluoro-
4-(N-1-
(4-carbobenzoxy)piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methanol (VI,
EXAMPLE
5, 1.0099 g, 1.643 mmol), isopropanol (5.6 ml), acetonitrile (9.0 ml),
benzaldehyde
(0.50 ml, 4.92 mmol) and aqueous ammonia (29.8 wt% 9.5 ml, 148.6 mmol) are
mixed. The mixture is stirred at 40° for 21.5 hrs, then concentrated
under reduced
pressure. Toluene (13.3 ml) and ethanol (6.0 ml) are added and the mixture
warmed
in a 70° bath. Citric acid monohydrate (2.433 g, 11.58 mmol) was then
added over
32
CA 02557862 1997-03-28
3.5 hrs and the phases separated at 64°. The organic phase is washed
with water
(2.5 ml) at 64°. The combined aqueous layers are washed with toluene
(10 ml) at
64°. Toluene (10 ml) is then added to the aqueous and the mixture
cooled to 0°.
The precipitate is collected by vacuum filtration, washed with 0°
toluene (10 ml) and
0° water ( 10 ml) and dried to a solid. A portion of this solid (0.7301
g) is slurried in
water (10 ml) and methylene chloride (10 ml) and the pH adjusted from 2.78 to
13.92 with aqueous sodium hydroxide (50%, 0.3915 g, 4.90 mmol) at -4 to -
2°. The
mixture is warmed to 20-25° and sonicated with stirring for 0.5 hr.
Methylene
chloride (55 ml), saturated aqueous sodium chloride (5 ml) and water (35 ml)
is
added and the phases separated. The aqueous phase is washed two times with
methylene chloride (25 ml) and the combined organics dried on sodium sulfate,
filtered and concentrated under reduced pressure. Toluene (5 ml) is added
followed
by a slow addition of heptane (25 ml). The resultant precipitate is collected
by
vacuum filtration, washed with heptane (20 ml) and dried to give the title
compound, TLC (silica gel; methanol/chloroform 10/90) Rf = 0.32; MS (EI), M/Z
(relative intensity) = 428 (28%,M+), 252 (15%), 92 (32%), 91 (100%); NMR
(CDC13,
300 MHz) 7.46, 7.38-7.27, 7.12, 6.90, 5.16, 4.69-4.60, 3.98, 3.80, 3.67, 3.09,
3.00-2.92
and 1.30 S; CMR (CDC13, 75 MHz) 43.94, 44.89, 47.60, 50.63, 67.23, 73.84,
107.29,
113.72, 119.37, 127.92, 128.07, 128.52, 133.79, 136.05, 136.64, 154.57, 155.19
and
155.61 8.
EXAMPLE 16 (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol 4-nitrobenzenesulfonate ester (VI)
To a slurry of (R)-[N-3-[3-ffuoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol (III, EXAMPLE 3, 43.0 g, 145 mmol) and triethylamine (36
g,
355 mmol) in methylene chloride (450 ml) at 0° is added a mixture of
4-nitrobenzenesulfonyl chloride (V, 32 g, 145 mmol) in methylene chloride (55
ml).
The mixture is stirred in a 0° bath for 30 min and then quenched with
hydrochloric
acid (10%, 200 ml). The organic phase is separated, and the aqueous phase is
extracted again with methylene chloride (200 ml). The combined organic
extracts
are then concentrated column chromatographed (silica gel, 4 cm X 6", 40-63 u;
methanol/methylene chloride 1-2/98-99, about 81). The appropriate fractions
are
combined and concentrated to give the title compound, Rf = 0.2; NMR (CDC13,
300
MHz) 8.73, 8.54, 8.23, 7.82, 7.33, 7.04, 6.91, 4.86, 4.42, 4.12, 3.86, and
3.05 8; CMR
(CDC13, 75 MHz, partial) 46.42, 50.89, 66.87, 69.09, 69.45, 107.45, 113.95,
118.84,
123.14, 128.73, 131.08, 133.28 and 137.27 b.
33
CA 02557862 1997-03-28
EXAMPLE 17 (S~[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methylamine salicylaldehyde imine
A mixture of (R,)-[N-3-(3-fluoro-4-(4-morpholinylphenyl)-2-oxo-5-
oxazolidinyl]methanol 3-nitrobenzenesulfonate ester (VI, EXAMPLE 16, 20.608 g,
42.803 mmol), isopropanol ( 149 ml), acetonitrile (245 ml), salicylaldehyde (
13.7 ml,
129 mmol) and aqueous ammonia (30%, 257 ml, 4.02 mol), is heated to 40°
and
stirred at 39-42° for 24 hrs. The mixture is then cooled to -22°
and the precipitate
collected by vacuum filtration, washed with water ( 10 ml) and dried to give
the title
compound, TLC (silica gel; methanol/chloroform 5/95) Rf. = 0.79; EIMS (m/z,
relative
intensity) = 399 (M+, 51) 234 ( 11), 196 ( 11), 149 (22), 135 ( 100), 134
(47); NMR (300
MHz, CDC13) 8.44, 7.41, 7.33-6.87, 4.96-4.88, 4.12, 3.94-3.84 and 3.04 b; CMR
(CDC13, 75 MHz) 48.21, 50.99, 61.94, 66.95, 71.30, 107.68, 114.12, 117.02,
118.43,
118.82, 119.01, 131.93, 133.04, 136.51, 154.24, 155.47, 160.78 and 168.87 8.
EXAMPLE 18 (S)-N-[[3-(3-Fluoro-4-morpholinylphenyl)-2-oxo-5-
oxazolidinyl]methyl]acetamide (VIII)
(S)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-oxazolidinyl]methylamine
salicylaldehyde imine (EXAMPLE 17, 1.0068 g, 2.521 mmol) Is slurried in water
( 10
ml) and 37% aqueous hydrochloric acid (0.417 ml, 5.04 mmol) and stirred at 20-
25°
for 15 hrs. Toluene (10 ml) is added and the phases separated; then, the
organic
phase is washed with hydrochloric acid (1M, 5 ml) and the combined aqueous
phases
are washed with toluene (10 ml). The toluene wash is back-extracted with
hydrochloric acid (1M, 5 ml). The combined aqueous phases are then adjusted to
pH
13.0 with aqueous sodium hydroxide (50%, 1.83 g, 22.9 mmol). To.the resultant
slurry is then added methylene chloride ( 10 ml) and sodium chloride ( 1 g)
and the
phases separated. The aqueous phase is then washed with methylene chloride (10
ml). To the combined organic phases is then added acetic anhydride (0.472 ml,
5.00
mmol) while maintaining 24-27°. The mixture is stirred 40 min, then
water is
added (5 ml). The phases are separated and the aqueous phase is washed with
methylene chloride (5 ml). The combined organic phases are concentrated and
ethyl
acetate (25 ml) is added. The mixture is warmed to 70° and then the
resultant
mixture is slowly cooled to -25°. The precipitate is collected by
vacuum filtration,
washed with -25° ethyl acetate (5 ml) and dried to give the title
compound, HPLC
major component (99.93 area % at 254 nm detection) retention time = 0.97 min,
column = Zorbax RX-C8, 250 X 4.6mm, mobile phase = 650 ml acetonitrile, 1.85
ml
triethylamine, 1.30 ml acetic acid and su~cient water to make 1000 ml; flow
rate =
*Trade-mark
34
CA 02557862 1997-03-28
3m1/min.
EXAMPLE 19 (R)-[N-3-[3-Fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-
oxo-5-oxazolidinyl]methanol (III)
A mixture of N-carbobenzoxy-3-fluoro-4-(N-carbobenzoxypiperazinyl)aniline
(II, 2.014 g, 4.345 mmol) and THF (10 ml) is cooled to -20°. In a
separate flask, a
solution of t-amyl alcohol (0.71 ml, 6.48 mmol) in THF (10 ml) at -33°
is treated with
n-butyllithium in heptane (13.65 wt%, 2.53 g, 5.38 mmol) while maintaining the
mixture at less than -20°. The resultant lithium t-amylate solution is
then added to
the N-carbobenzoxy-3-fluoro-4-(N-carbobenzoxypiperazinyl)aniline mixture while
maintaining less than -20° and rinsed in with THF (4 ml). To the
resulting mixture
at -28° is then added S-glycidol (IV, 0.3360 g, 4.536 mmol). The
mixture is then
stirred at -20° for 1.5 hrs, then at -16° for 17 hrs, at -
11° for 4 hrs then at -1° for 2
hrs. HPLC assay then showed the major component to have a retention time
consistent with the title compound (90.4 area % at 254 nm detection; retention
time
= 1.30 min; column = Zorbax RX-C8, 250 X 4.6 mm; mobile phase = 650 ml
acetonitrile, 1.85 ml triethylamine, 1.30 ml acetic acid and add sufficient
water to
make 1000 ml; flow rate = 3 ml/min) as did TLC (silica gel;
methanol/chloroform
10/90) Rf = 0.60.
EXAMPLE 20 (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol 4-nitrobenzenesulfonate ester (VI)
Following the general procedure of EXAMPLE 16 and making non-critical
variations but starting with 4-nitrobenzenesulfonyl chloride, the title
compound is
obtained.
EXAMPLE 21 (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol 2-nitrobenzenesulfonate ester (VI)
Following the general procedure of EXAMPLE 16 and making non-critical
variations but starting with 2-nitrobenzenesulfonyl chloride, the title
compound is
obtained.
EXAMPLE 22 (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol 2,4-dinitrobenzenesulfonate ester (VI)
Following the general procedure of EXAMPLE 16 and making non-critical
variations but starting with 2,4-dinitrobenzenesulfonyl chloride, the title
compound
is obtained.
EXAMPLE 23 (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol 4-chlorobenzenesulfonate ester (VI)
CA 02557862 1997-03-28
Following the general procedure of EXAMPLE 16 and making non-critical
variations but starting with 4-chlorobenzenesulfonyl chloride, the title
compound is
obtained.
EXAMPLE 24 (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]-2-oxo-5-
oxazolidinyl]methanol 2,5-dichlorobenzenesulfonate ester (VI)
Following the general procedure of EXAMPLE 16 and making non-critical
variations but starting with 2,5-dichlorobenzenesulfonyl chloride, the title
compound
is obtained.
36
CA 02557862 1997-03-28
CHART A
M1-CH2-CH(OH)-CH2-OH (I)
10 R 1-NH-CO-O-M2 (IIA)
or
R1-NH-CO-CF3 (IIB)
20
O
R1 ~
N O
(III)
~ - H
CH2 - pH
37
CA 02557862 1997-03-28
CHART B
C*H2-C*H-CH2-OH (IV)
where the carbon atoms designated by an * are each bonded to the same oxygen
atom (-0-) to form a three member ring Qr epoxide
+
R1-NH-CO-O-M2 (IIA)
or
R1-NH-CO-CF3 (IIB)
25
O
R1 \
N O
(III)
~- H
CH2 OH
38
CA 02557862 1997-03-28
CHART C
O
R~ \
N O (III)
~_H
~ CH2 OH
M3-S02-C6Hn3(N02)nlCln2 (Va)
O[-S02-C6Hn3(N02)n1C1n2]2 (Vb)
0(s~2-F)2 (Vc)
O(S02-CF3)2 (Vd)
O
(VIa or b)
~ \N O
~- H
CH2- O - S02- CgHn3 ~N02)~~ Cfn2
O
R~ \
N O (VIc)
CH2 - O - S02 - F
0
R1 \
N O (VId)
CH2 O - S02 CF3
O
R1 \
N O
- H (VII)
CH2 NH2
39
CA 02557862 1997-03-28
~HAR.T D
O
R~ ~
N O
- H (VII)
CH2 NH2
15
0
Ri
~N O
-H
CH2 - NH - CO - R2 ,
30
